PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.44%
EBIT growth of 10.44% while Biotechnology median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
10.44%
Operating income growth of 10.44% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand.
10.28%
Net income growth of 10.28% while Biotechnology median is zero. Walter Schloss might see potential if moderate gains can keep rising.
12.12%
EPS growth of 12.12% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
10.49%
Diluted EPS growth of 10.49% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
2.21%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.06%
Negative OCF growth while Biotechnology median is -2.62%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-28.93%
Negative FCF growth while Biotechnology median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4997.65%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
52.56%
OCF/share CAGR of 52.56% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
56.42%
3Y OCF/share growth of 56.42% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-10058.37%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
92.69%
Net income/share CAGR of 92.69% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
51.37%
3Y net income/share CAGR of 51.37% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
741.48%
Equity/share CAGR of 741.48% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
108.54%
5Y equity/share CAGR of 108.54% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
-89.94%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.83%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-40.69%
Negative BV/share change while Biotechnology median is -4.00%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
499.58%
Debt growth of 499.58% while Biotechnology median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
-14.73%
R&D dropping while Biotechnology median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
3.54%
SG&A growth of 3.54% while Biotechnology median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.